ArticleOxford medical case reports2026
Cavitating mesenteric lymph node syndrome: a rare complication of celiac disease-case report and literature review.
Article in Oxford medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCavitating Mesenteric Lymph Node Syndrome (CMLNS) is an uncommon complication of celiac disease, characterized by cystic mesenteric lymph nodes and high morbidity. CASE PRESENTATION: A 46-year-old male with chronic diarrhea, vomiting, and weight loss had hypoalbuminemia and elevated anti-TTG IgA. Duodenal biopsy confirmed celiac disease (Marsh IIIb). CT showed pseudocystic mesenteric lymph nodes and splenic atrophy, initially suggesting malignancy. Laparoscopic excision revealed cavitated lymph nodes with liquefactive necrosis and an inflammatory rim, excluding lymphoma or infection. The patient received a gluten-free diet, nutritional support, and corticosteroids, achieving clinical improvement and stable imaging at six months.
conclusionCMLNS should be considered in celiac patients with refractory symptoms and atypical imaging. Early recognition through clinical, radiological, and pathological assessment, combined with a gluten-free diet and supportive care, is crucial to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.